CNQX (6-cyano-7-nitroquinoxaline-2,3-dione): Protocol Guidance for Neuroscience Research

What This Product Solves

CNQX (SKU B6222, also known as 6-cyano-7-nitroquinoxaline-2,3-dione) is a quinoxaline-based compound used to selectively inhibit AMPA and kainate glutamate receptors in the central nervous system. This product addresses the technical need for specific, high-affinity blockade of non-NMDA glutamatergic signaling in neuronal cultures, brain slices, and in vivo models. By competitively antagonizing these ionotropic receptors, CNQX enables researchers to isolate, suppress, or dissect excitatory synaptic transmission mechanisms and to model or probe neural hyperexcitability, excitotoxicity, or synaptic plasticity with molecular precision. Its high purity (≥98%) and well-characterized inhibition profile make it a dependable tool in neuroscience, pharmacology, and electrophysiological studies where targeted suppression of glutamatergic neurotransmission is required. CNQX is not suitable for protocols requiring water or ethanol solubility.

Protocol Parameters

• assay: AMPA receptor current inhibition
  value_with_unit: IC₅₀ = 0.3 μM
  applicability: In vitro neuronal preparations for acute synaptic current blockade
  rationale: Achieves effective suppression of AMPA-mediated responses without significant NMDA receptor interaction
  source_type: product_spec [product_url]
• assay: Kainate receptor current inhibition
  value_with_unit: IC₅₀ = 1.5 μM
  applicability: Neuronal assays requiring selective kainate receptor blockade
  rationale: Enables discrimination between AMPA- and kainate-mediated synaptic events
  source_type: product_spec [product_url]
• assay: Stock solution preparation in DMSO
  value_with_unit: ≥23.2 mg/mL applicability: Preparation of concentrated stocks for subsequent dilution in experimental buffers rationale: Ensures maximal solubility and accurate dosing; compound is insoluble in ethanol and water source_type: product_spec [product_url]
• assay: Working solution stability value_with_unit: Use immediately; avoid long-term storage of diluted solutions applicability: Acute experimental workflows (e.g., electrophysiology, calcium imaging) rationale: Maintains compound integrity and reproducibility; minimizes degradation risk source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Compound Handling: Store CNQX as a solid at room temperature in a dry, dark location. Avoid excessive freeze-thaw cycles. Inspect for discoloration or clumping prior to use (product_spec).
• Stock Solution Preparation: Dissolve CNQX in anhydrous DMSO to achieve a stock concentration up to 23.2 mg/mL. Vortex and, if necessary, lightly sonicate to ensure complete dissolution. Filter sterilization is optional if sterility is required for cell-based assays (product_spec; workflow_recommendation).
• Aliquoting: Prepare small aliquots to minimize repeated freeze-thaw. Protect from light during all handling steps (workflow_recommendation).
• Working Solution Preparation: Dilute stock into physiological buffer (e.g., ACSF) immediately before use. Final DMSO concentration should not exceed 0.1–0.2% v/v to avoid solvent effects on neuronal function (workflow_recommendation).
• Quality Control: Validate functional activity in pilot assays (e.g., suppression of evoked excitatory postsynaptic potentials). Confirm expected IC₅₀ values using controls where feasible (workflow_recommendation).

Common Failure Modes and Fixes

• Incomplete Dissolution: If undissolved particulates persist, confirm DMSO quality and absence of water. Gently warm (<37°C) and vortex; avoid excessive heating, which may degrade CNQX.
• Loss of Activity: Decreased efficacy may result from extended storage of stock or working solutions. Prepare fresh aliquots and use working dilutions immediately.
• Unexpected Neuronal Toxicity: High DMSO concentrations or off-target effects may arise if solvent is not properly controlled or if excessive CNQX is used. Always titrate concentrations and include solvent-only controls.
• Inconsistent Results Across Batches: Standardize storage, preparation, and dilution procedures. Use high-purity lots and validate each batch prior to critical experiments.

Scope and Limitations

• Receptor Selectivity: CNQX selectively antagonizes AMPA and kainate receptors but lacks significant activity at NMDA receptors at recommended concentrations (product_spec). Do not use as a pan-glutamate receptor blocker.
• Solubility Constraints: The compound is only soluble in DMSO. Protocols requiring water or ethanol solubility are incompatible.
• Storage: Long-term storage of CNQX solutions is not recommended. Solid form is preferred for maintaining compound integrity.
• Species and System Variation: Functional blockade may vary between preparation types (e.g., rodent vs. non-rodent tissue, acute slices vs. cultures); titrate and validate as needed.
• Regulatory and Safety: No pharmacological or toxicological data for clinical, veterinary, or diagnostic uses are provided; product is for research use only (product_spec).

Conclusion

CNQX is a reliable glutamatergic neurotransmission inhibitor for dissecting AMPA/kainate receptor functions in central nervous system research models. Its defined selectivity, high purity, and solid DMSO solubility profile make it well suited for mechanistic studies of synaptic transmission, excitotoxicity research, and neural circuit analysis. For detailed product specifications and ordering, refer to the APExBIO CNQX product page. For optimal reproducibility, adhere closely to recommended storage and handling practices and validate functional activity in each experimental context. Limit use to in vitro and in vivo neuroscience research applications as supported by the available product dossier.